Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (330)	12/11/1998 9:41:00 AM
From: yosi s	Read Replies (1) \| Respond to of 1386

Looks like no one is jumping fast. With Phase 2 3rd cohort having 30 patients 20 of which are to be in active arm.(getting HU211.) this will increase the number of patients from 30 to 50 . I feel, and this is my speculation only. that a potential partner wants more confirmation of DATA and they will wait or draw negotiation until phase 2 is over. Otherwise: by now they must be close to making a deal. And I see no evidence for a partner to sign up soon.... The Only thing that can Help the stock is Sales of Alrex and Lotemax. Here we are hindered by lack of progress: 1. Alrex not being actively promoted to Alergists. ( If you argued that the season was over, well the weather was quite warm and the season exceptionally longer. Yet that segment of the market over 25% is neglected. Same goes for introduction into Europe and other markets. Also Letobra should help. Yet here again there were numerous changes of strategies of how to proceed. So far lots & lots of growing pain . It will take a lot of show me before management gains credibility